A Phase 1/2 interventional study of Ibrutinib and Pomalidomide in Multiple Myeloma, sponsored by Pharmacyclics LLC.. Terminated at 16 sites in 6 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2019-11-21.
Sponsored by Pharmacyclics LLC. (part of AbbVie) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Multiple Myeloma by AbbVie — 7 open to participants now, 17 under way, 5 of them phase 3. Multiple Myeloma · AbbVie.
Among the 40 studies in Multiple Myeloma by AbbVie, this one is the 31st largest by enrollment of the 39 interventional ones that give a count, is one of 3 that started in 2016, is one of 7 in phase 1/2, and was the 14th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →7 of the 40 studies in Multiple Myeloma by AbbVie are open now, in 12 countries. Recruiting first, the newest first:
AbbVie · Sites in United States, China, Israel and 1 more country
Ages 18+
AbbVie · Sites in United States, France, Japan and 1 more country
Ages 18+
AbbVie · Sites in United States, Australia, Canada and 4 more countries
Ages 18+
AbbVie · Sites in United States, Australia, Belgium and 9 more countries
Ages 18+
AbbVie · Sites in United States, Australia, Israel and 3 more countries
Ages 18+
By country, each count listing its studies:
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 16 · Phase 3 6
First in 2005; this study’s year is marked. 3 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 11 is below the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 84 across the 39 interventional studies, 514 across the 1 observational. Of the 21 that completed or were terminated, 8 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Pharmacyclics LLC., one of the names counted as AbbVie. Under that name alone:
Pharmacyclics LLC. is the lead sponsor of 54 studies on the registry; none are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 9 (90%) have results posted.
3 of the studies in Multiple Myeloma by AbbVie that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03844048Phase 3AbbVieAn Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | 2027-08 |
| NCT06223516AbbVieStudy of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma | 2027-02 |
| NCT02899052AbbVieStudy of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM) | 2027-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 40 studies in Multiple Myeloma by AbbVie, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Phase 1 is an open-label, dose finding, multicenter study of ibrutinib in combination with pomalidomide and dexamethasone in subjects with relapsed/refractory multiple myeloma.
Phase 2b is a randomized, double-blind, multicenter study of ibrutinib or placebo, in combination with pomalidomide and dexamethasone in subjects with relapsed/refractory multiple myeloma.
Bruton's tyrosine kinase (Btk) is an enzyme that is present in hematopoietic cells other than T cells and is necessary for downstream signal transduction from various hematopoietic receptors including the B cell receptor as well as some Fc, chemokine, and adhesion receptors, and is crucial for both B cell development and osteoclastogenesis. Although down-regulated in normal plasma cells, Btk is highly expressed in the malignant cells from many myeloma patients and some cell lines. Ibrutinib is a potent and specific inhibitor of Btk currently in Phase 2 and 3 clinical trials. The current study is designed and intended to determine the safety and efficacy of ibrutinib in combination with pomalidomide and dexamethasone in subjects with relapsed/refractory multiple myeloma.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
defined by at least ONE of the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ibrutinib PO+ Pomalidomide PO+ Dexamethasone PO
Drug: Ibrutinib · Drug: Pomalidomide · Drug: Dexamethasone
Ibrutinib PO+ Pomalidomide PO+ Dexamethasone PO
Drug: Ibrutinib · Drug: Pomalidomide · Drug: Dexamethasone
Placebo PO+ Pomalidomide PO+ Dexamethasone PO
Drug: Pomalidomide · Drug: Dexamethasone · Drug: Placebo
Overall Response Rate (ORR) According to the IMWG Response Criteria Per Investigator Assessment
The overall response rate, defined as the proportion of subjects achieving a best overall response of PR or better per investigator assessment per IMWG at or prior to initiation of subsequent anticancer therapy
Time frame: 14 Months
Clinical Benefit Response (CBR)
The clinical benefit response, defined as the proportion of subjects achieving a best overall response of MR or better per investigator assessment per IMWG at or prior to initiation of subsequent anticancer therapy.
Time frame: 14 Months
Duration of Response (DOR)
The time interval between the date of initial documentation of a response and the date of first documented evidence of progressive disease, death, or date of censoring for the subjects not progressed/died. The censoring date is the last adequate tumor assessment date.
Time frame: 14 Months
| Milestone | Phase 1: Dose Finding (560mg) | Phase 1: Dose Finding (840mg) |
|---|---|---|
| Started | 8 | 3 |
| Completed | 7 | 3 |
| Not completed | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
The overall response rate, defined as the proportion of subjects achieving a best overall response of PR or better per investigator assessment per IMWG at or prior to initiation of subsequent anticancer therapy
| Participants | Phase 1: Dose Finding (560mg) | Phase 1: Dose Finding (840mg) |
|---|---|---|
| Overall Response Rate (ORR) According to the IMWG Response Criteria Per Investigator Assessment | 3 | 1 |
The clinical benefit response, defined as the proportion of subjects achieving a best overall response of MR or better per investigator assessment per IMWG at or prior to initiation of subsequent anticancer therapy.
| Participants | Phase 1: Dose Finding (560mg) | Phase 1: Dose Finding (840mg) |
|---|---|---|
| Clinical Benefit Response (CBR) | 4 | 2 |
The time interval between the date of initial documentation of a response and the date of first documented evidence of progressive disease, death, or date of censoring for the subjects not progressed/died. The censoring date is the last adequate tumor assessment date.
| Months | Phase 1: Dose Finding (560 mg) | Phase 1: Dose Finding (840 mg) |
|---|---|---|
| Duration of Response (DOR) | 6.5 (5.1 to 11.8) | 7.3 (7.3 to 7.3) |
Collected over 14 Months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1: Dose Finding (560mg) | 1/8 (12.5%) | 8/8 (100%) | 8/8 (100%) |
| Phase 1: Dose Finding (840mg) | 1/3 (33.3%) | 3/3 (100%) | 3/3 (100%) |
| Event | Phase 1: Dose Finding (560mg) | Phase 1: Dose Finding (840mg) |
|---|---|---|
| PneumoniaInfections and infestations | 1/8 | 1/3 |
| Urinary Tract InfectionInfections and infestations | 1/8 | 1/3 |
| Cardiac FailureCardiac disorders | 0/8 | 1/3 |
| DehydrationMetabolism and nutrition disorders | 0/8 | 1/3 |
| EmbolismVascular disorders | 0/8 | 1/3 |
| Subdural HaemorrhageInjury, poisoning and procedural complications | 0/8 | 1/3 |
| Atrial FibrilationCardiac disorders | 1/8 | 0/3 |
| Cardio-respiratory ArrestCardiac disorders | 1/8 | 0/3 |
| DiarrhoeaGastrointestinal disorders | 1/8 | 0/3 |
| Febrile NeutropeniaBlood and lymphatic system disorders | 1/8 | 0/3 |
| Event | Phase 1: Dose Finding (560mg) | Phase 1: Dose Finding (840mg) |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 6/8 | 2/3 |
| DiarrhoeaGastrointestinal disorders | 2/8 | 2/3 |
| NauseaGastrointestinal disorders | 2/8 | 2/3 |
| FatigueGeneral disorders | 5/8 | 2/3 |
| ThrombocytopeniaBlood and lymphatic system disorders | 4/8 | 1/3 |
| NeutropeniaBlood and lymphatic system disorders | 4/8 | 0/3 |
| Upper Respiratory Tract InfectionInfections and infestations | 4/8 | 0/3 |
| Increased Tendency to BruiseBlood and lymphatic system disorders | 0/8 | 1/3 |
| Spontaneous HaematomaBlood and lymphatic system disorders | 0/8 | 1/3 |
| TachycardiaCardiac disorders | 0/8 | 1/3 |
| Age, Categorical(Participants) | Phase 1: Dose Finding (560mg) | Phase 1: Dose Finding (840mg) | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 5 | 0 | 5 |
| >=65 years | 3 | 3 | 6 |
| Age, Continuous(years) | Phase 1: Dose Finding (560mg) | Phase 1: Dose Finding (840mg) | Total |
|---|---|---|---|
| Median | 63.5 (53 to 81) | 72.7 (67 to 77) | 67.5 (53 to 81) |
| Sex: Female, Male(Participants) | Phase 1: Dose Finding (560mg) | Phase 1: Dose Finding (840mg) | Total |
|---|---|---|---|
| Female | 3 | 3 | 6 |
| Male | 5 | 0 | 5 |
| Ethnicity (NIH/OMB)(Participants) | Phase 1: Dose Finding (560mg) | Phase 1: Dose Finding (840mg) | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 2 |
| Not Hispanic or Latino | 6 | 2 | 8 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Region of Enrollment(participants) | Phase 1: Dose Finding (560mg) | Phase 1: Dose Finding (840mg) | Total |
|---|---|---|---|
| Greece | 3 | 0 | 3 |
| United States | 3 | 0 | 3 |
| Czechia | 2 | 2 | 4 |
| Australia | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Mar 2016, a primary completion of Jun 2018 and a completion of Jun 2018. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2019, 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ibrutinib